Icon

FARYDAK (nda205353)- (EQ 10MG BASE,EQ 15MG BASE,EQ 20MG BASE)

PANOBINOSTAT LACTATE SECURA
EQ 10MG BASE,EQ 15MG BASE,EQ 20MG BASE
No No
2028-Jun-13 2020-Feb-23
2022-Feb-23 None
None No
FARYDAK, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 10MG BASE ** ** - - -
EQ 15MG BASE ** ** - - -
EQ 20MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.